Promoted Content
Promoted Content

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Loading...

All Data

Filters Filter refresh
×
FILTER DATA :
News Type filter
    Company filter
      Product Type filter
        Deal Size filter
          Upfront Payment filter
            refresh

            Product Type Full Screen

            Companies Full Screen

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Lenzilumab

            Therapeutic Area: Immunology Product Name: Humaneered

            Highest Development Status: Phase III Product Type: Large molecule

            Partner/Sponsor/Collaborator: Humanigen

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Expanded Collaboration January 27, 2021

            Details:

            Aji Bio-Pharma will assume a key role in simplifying the supply chain efforts for Humanigen by providing lenzilumab's aseptic fill finish services at its San Diego facility to support continued clinical trial efforts through potential commercialization.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Efgartigimod

            Therapeutic Area: Immunology Product Name: ARGX-113

            Highest Development Status: Phase III Product Type: Large molecule

            Partner/Sponsor/Collaborator: Zai Lab

            Deal Size: $175.0 million Upfront Cash: $75.0 million

            Deal Type: Collaboration January 06, 2021

            Details:

            Collaboration to expand and accelerate global development of efgartigimod; expected to allow argenx to more rapidly advance new potential indications into clinical development each year.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Filgotinib

            Therapeutic Area: Immunology Product Name: Jyseleca

            Highest Development Status: Phase III Product Type: Small molecule

            Partner/Sponsor/Collaborator: Gilead Sciences

            Deal Size: $193.8 million Upfront Cash: Undisclosed

            Deal Type: Collaboration December 15, 2020

            Details:

            Under the terms of the amended agreement, Galapagos will assume operational responsibility for ongoing clinical trials evaluating filgotinib in RA. Gilead will not advance Jyseleca for the treatment of Rheumatoid Arthritis (RA) in the U.S. following FDA Type A Meeting.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Efgartigimod

            Therapeutic Area: Immunology Product Name: ARGX-113

            Highest Development Status: Phase III Product Type: Large molecule

            Partner/Sponsor/Collaborator: Argenx BVBA

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Agreement November 23, 2020

            Details:

            Argenx has agreed to acquire a U.S. Food and Drug Administration (FDA) Priority Review Voucher (PRV) from Bayer Healthcare Pharmaceuticals. argenx expects to redeem the PRV for a future marketing application for its FcRn antagonist efgartigimod.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Bimekizumab

            Therapeutic Area: Immunology Product Name: UCB4940

            Highest Development Status: Phase III Product Type: Large molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable November 05, 2020

            Details:

            Long-term findings from Phase 2b studies on UCB’s investigational IL-17A and IL-17F inhibitor, bimekizumab, demonstrateconsistent durability of clinical responses in patients with ankylosing spondylitis (AS) and psoriatic arthritis (PsA).

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Certolizumab Pegol

            Therapeutic Area: Immunology Product Name: Undisclosed

            Highest Development Status: Phase III Product Type: Large molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable June 04, 2020

            Details:

            Four-year results from the RAPID-axSpA study of CIMZIA[®] (certolizumab pegol) highlight the importance of early, effective and long-term treatment targeting inflammation.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Efgartigimod

            Therapeutic Area: Immunology Product Name: Undisclosed

            Highest Development Status: Phase III Product Type: Large molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable May 26, 2020

            Details:

            ADAPT met its primary endpoint defined as percentage of responders on the Myasthenia Gravis Activities of Daily Living (MG-ADL) score among acetylcholine receptor-antibody positive (AChR-Ab+) generalized myasthenia gravis (gMG) patients.